Allergy Therapeutics Plc (AGY) Ord GBP0.01

Sell:6.00pBuy:7.00pNo change

Prices delayed by at least 15 minutes
Sell:6.00p
Buy:7.00p
Change:No change
Prices delayed by at least 15 minutes
Sell:6.00p
Buy:7.00p
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

Key people

Manuel Llobet
Chief Executive Officer, Executive Director
Shaun Antony Furlong
Chief Financial Officer, Executive Director
Karley Cheesman
Company Secretary
Peter Sinclair Jensen
Non-Executive Chairman of the Board
Anthony Michael Parker
Non-Executive Director
Zheqing Shen
Non-Executive Director
David William Dawson Ball
Non-Executive Independent Director
Cheryl Faye Macdiarmid
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    AGY
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00B02LCQ05
  • Market cap
    £328.88m
  • Employees
    602
  • Shares in issue
    4.77bn
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.